- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc stock price live, this page displays NASDAQ LXRX stock exchange data. View the LXRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lexicon Pharmaceuticals Inc real time stock price chart below.
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 1.070.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is ""LXRX.""
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 1.070.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is ""LXRX.""
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
1.070
-0.020(-1.83%)
Closed·
After Hours
1.080+0.010(+0.93%)
·
Fair Value
An estimate of a Lexicon's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.030
1.080
52 wk Range
0.284
2.390
LXRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 7 days
More Info
Fair Value
An estimate of a Lexicon's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0301.080
52 wk Range
0.2842.390
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LXRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Lexicon's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
2.580
Upside
+141.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Lexicon Pharmaceuticals Inc For: 28 July
- Investing.com
- Form 8K Lexicon Pharmaceuticals Inc For: 28 July
- Investing.com
- Form 8K Lexicon Pharmaceuticals Inc For: 3 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Lexicon Pharmaceuticals Inc Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of -$0.07 beat expectations, but revenue of $1.26M fell short of $2.82M forecast; stock declined 6.51% after hours
- Secured $45M upfront payment from Novo Nordisk; announced positive Phase 2b results for pilavapitan in diabetic peripheral neuropathic pain
- R&D expenses increased to $15.3M; SG&A decreased to $11.6M; net loss reduced to $25.3M from $48.4M in Q1 2024
- Anticipates 2025 operating expenses of $135-$145M; R&D expenses projected at $100-$105M; focusing on pilavapitan and sotagliflozin programs
- CEO emphasized commitment to pilavapitan development; CMO highlighted strategic importance of hypertrophic cardiomyopathy study
Last Updated: 13/05/2025, 23:04
Read Full TranscriptCompare LXRX to Peers and Sector
Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −1.7x | −0.5x | |
PEG Ratio | −0.06 | −0.07 | 0.00 | |
Price/Book | 3.2x | 0.8x | 2.6x | |
Price / LTM Sales | 12.4x | 44.2x | 3.2x | |
Upside (Analyst Target) | 13.7% | 218.8% | 42.0% | |
Fair Value Upside | Unlock | 34.0% | 6.6% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.580
(+141.12% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.07 / -0.12
Revenue / Forecast
1.26M / 2.82M
People Also Watch
FAQ
What Stock Exchange Does Lexicon Trade On?
Lexicon is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Lexicon?
The stock symbol for Lexicon is "LXRX."
What Is the Lexicon Market Cap?
As of today, Lexicon market cap is 395.86M.
What Is Lexicon's Earnings Per Share (TTM)?
The Lexicon EPS (TTM) is -0.51.
When Is the Next Lexicon Earnings Date?
Lexicon will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is LXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Lexicon Stock Split?
Lexicon has split 1 times.
How Many Employees Does Lexicon Have?
Lexicon has 103 employees.
What is the current trading status of Lexicon (LXRX)?
As of 30 Jul 2025, Lexicon (LXRX) is trading at a price of 1.07, with a previous close of 1.07. The stock has fluctuated within a day range of 1.03 to 1.08, while its 52-week range spans from 0.28 to 2.39.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.